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1. Introduction
The prevalence of kidney disease has grown continuously. The loss of kidney function during
acute kidney disease may occur rapidly and reversibly, and most unfortunately, may progress
to end-stage renal disease (ESRD) in which renal replacement therapy (RRT) is required. Due
to the short supply of donor kidneys, RRT is now dominated by dialysis. Dialysis can be
applied intermittently or continuously using extracorporeal (hemodialysis or HD) or para‐
corporeal (peritoneal dialysis or PD) methods. Among patients with ESRD, the choice of PD
or HD varies considerably from country to country and is related to non-medical factors such
as finance, physician preferences, and social culture [1]. It has been suggested that PD should
be offered as the first-line dialysis modality [2]. Compared with HD, PD offers better preser‐
vation of residual renal function, lower risk of infection with hepatitis B and C, better outcome
after transplantation, preservation of vascular access, easy to place on home therapy, simplicity
of the technique, and lower costs [3, 4]. The predominant problems associated with PD are
ultrafiltration failure and peritonitis. Dialysis patients after an episode of peritonitis may still
be affected by prolonged systemic chronic inflammation [5]. Likewise, PD maintains a state of
intraperitoneal micro-inflammation that affects the structure and function of the peritoneal
membrane, and impairs ultrafiltration efficiency. An understanding of the mechanism in
peritoneal inflammation will provide new insight to better preserve the function of the
peritoneum membrane, with a goal to improve the quality of life in patients under PD.
2. Inflammatory response during peritoneal dialysis
Inflammation is the body's natural defense involving cascades of immediate immunological
responses towards various stimuli, including pathogens, necrotic cells, injury, or irritants.
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Acute inflammation is a protective machinery by which the injurious stimuli will be removed
and the healing process initiated. On the other hand, chronic inflammation develops if the
conditions causing acute inflammation is not resolved over a period of time. Intriguingly,
chronic inflammation may be due to excessive physiological responses, such as the wound
repairing process, which are intrinsically essential for maintaining normal life. Certain stimuli
may directly provoke chronic rather than acute inflammation. Peritoneal inflammation of the
microenvironment in the peritoneal cavity during PD generally presents in two major forms:
(i) acute inflammation triggered by microbial infection, and (ii) low-grade inflammation or
"para-inflammation" under various exogenous or endogenous stimulations during PD. These
two forms of inflammation affects the membrane structure and function, and is associated with
increased mortality.
2.1. Acute inflammation in PD
The most common form of acute inflammation of peritoneum in PD is peritonitis, which is a
serious and the most frequent complication leading to hospitalization and catheter loss [6, 7].
Peritonitis causes a high infection-related mortality in PD patients [8, 9]. The leading cause of
PD-associated peritonitis is contamination, predominately with the microorganisms from skin
and environment, which is most commonly occur during the dialysis procedure such as PD
exchange [10]. Exit site infection (ESI) in which transmigration of microorganisms from the
exit site along the PD catheter into the peritoneal cavity, may cause tunnel infections and
peritonitis [11, 12]. Enteric peritonitis is a less common cause but important, due to the severity
of the inflammation process [13]. Fungal peritonitis accounts for about 4–6% of episodes of the
total incidence of the peritonitis, and is with high mortality [14]. Rapidly resolving the infection
is the primary approach to treat peritonitis, even if this involve the need for prompt removal
of the peritoneal catheter. Before the causative microorganism is identified, initial therapy with
broad spectrum antibiotic which is active against the most commonly occurring organisms,
will be given according to the guideline from the International Society for Peritoneal Dialysis
(ISPD) [9]. It is recommended that in addition to the standard initial protocol, specific regime
tailored to the geographic and cultural characteristics, the relevant organisms and their
antibiotic resistance pattern should be considered [15]. Detailed examination of the causality
of infection-related peritonitis is important for the management. The molecular pathways of
inflammation induced by different microbial pathogens are somehow redundant, yet also
complex and diverse [16, 17].
2.2. Chronic inflammation in PD
An inherent immune dysfunction in PD patients and the continuous non-specific immune cell
stimulation by dialysis procedure contribute to the chronic inflammatory state of patients
under the long-term dialysis [18]. Patients on maintenance PD have increased intra-peritoneal
levels of hyaluronan and cytokines including interleukin (IL)-1β, IL-6 and transforming
growth factor-β (TGF-β) [19, 20]. Chronic inflammation remains an important cause of
morbidity in patients with ESRD. During continuous ambulatory peritoneal dialysis (CAPD),
peritoneal cells are repeatedly exposed to non-physiologic dialysis fluid (PDF) with low pH
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and high glucose [21]. PDF also contains toxic substance like glucose degradation products
(GDP) generated during the sterilization process and the advanced glycation end products
(AGE), which can be formed by amadori reaction between sugar and protein during long-term
PD [22]. Dialysis patients are likely to gain fat mass following absorption of glucose from the
peritoneal dialysate [23]. Adipocyte in adipose tissue is the major source of adipokines such
as leptin, adiponectin and other inflammatory mediators. Adipose tissue is also an important
contributor to the peritoneal and systemic inflammation [24, 25]. Exposure of peritoneal cells
to the non-physiological dialysate during CAPD leads to "para-inflammation" [26], which is a
protective mechanism helping the peritoneum to adapt to the noxious conditions during PD
and to restore peritoneum functionality. Regrettably, after repeated exposure to various insults
in PDF, dysregulated para-inflammation may eventually develop chronically to inflammatory
states associated with ultrafiltration failure. A key feature of chronic inflammation is peritoneal
fibrosis [27, 28], in which fibroblasts proliferate or are recruited to the inflamed peritoneum
with the activation of cascades of inflammatory or fibrotic cytokines [29, 30].
3. The Mechanisms and pathways of inflammation in PD
The inflammatory pathway of PD consists of modulators, mediators and effectors. A simplified
schema for PD-related inflammation is illustrated in Figure 1. The complex interaction among
the components involved and the related machinery will determine the outcome of the
immune response induced by PD.
3.1. Modulators:
Modulators of PD-related inflammation can be exogenous or endogenous. It should be noted
that exogenous modulators may promote or amplify the effects of the endogenous modulators
during the process of PD-related inflammation. Intriguingly, the interaction between modu‐
lators and the ongoing inflammatory events may form a vicious cycle to amplify the inflam‐
matory process.
3.1.1. Exogenous modulators
The innate immune system recognized catheters used for PD as the foreign bodies. Severe
biofilm formation on the catheters have been observed in PD patients without detectable
infection [31]. Histologic and functional evidences obtained from rodent model have shown
that the catheter insertion may have induced a classic inflammatory reaction characterized by
formation of fibrin clots in the peritoneum [32]. Mechanical stress during PD is related to the
infiltration of large volume of PDF, especially for achieving specific target of small solute
clearance. Volume stress during PD are associated with significant increments in endothelin
(ET)-1, a vasoactive peptide that may induce peritoneal fibrosis and indirectly contribute to
technique failure in CAPD [33]. ET-1 induces the release of proinflammatory cytokines and
increases the deposition of extracellular matrix (ECM) by regulating production and turnover
of matrix components. In addition, high fill volumes increase circulating norepinephrine levels
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[34], blood pressure, intraperitoneal pressure [35], and elicit proinflammatory effects by
increasing peritoneal IL-6 and tumor necrosis factor-α (TNF-α) concentration [36]. During PD,
cells lining the peritoneal cavity are exposed from time to time to the hyperosmotic environ‐
ment, and this osmotic stress induces apoptosis of the peritoneal cells [37, 38]. Local acidosis
occurs artificially during PD due to the non-physiological properties of PDF which has an
acidic pH value. Exposure of macrophages to an acidic environment leads to the increased
production of TNF-α through the up-regulation of inducible nitric oxide synthase (iNOS)
activity and the activation of nuclear factor-κB (NF-κB) [39]. On the contrary, low pH PDF lead
to rapid intracellular acidification and suppression of host defense activity [40, 41]. The acidic
PDF induces stress on the endoplasmic reticulum (ER) and suppresses the induction of
monocyte chemotactic protein-1 (MCP-1) in the peritoneum through de-activation of NF-κB
pathway [42, 43], and this may impair the peritoneal defense mechanisms by interfering with
migration of phagocytic cells. Obviously, further study is needed to clarify the role of acidic-
stress on PD-related inflammation. High glucose content in PDF induces immunological,
structural and functional abnormalities in peritoneal cells during CAPD [44, 45]. High glucose
induces vascular inflammatory processes through up-regulation of endothelial cell adhesion
molecules, reduction of nitric oxide (NO) release, activation of reactive oxygen species (ROS)
and NF-κB [46, 47]. Storage or heat sterilization of PDF generates the toxic substances GDP.
Dialysis with GDP-containing PDF is associated with increased vascular endothelial growth
Figure 1. Pathway of the development of PD-related inflammation
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factor (VEGF) production and peritoneal vascularization [48]. GDP decrease the expression of
tight junction associated protein, zonula occludens protein 1 (ZO-1), in human peritoneal
mesothelial cells (HPMC) via the VEGF [49]. Glucose or GDP in PDF may cause AGE formation,
which further provoke additional inflammatory stimuli on the peritoneal environment under
PD [22, 50, 51]. Contamination and the inherent poor immune status of the PD patients
contribute to the microbial stress during PD. Microbial contamination or ESI during PD may
evolve to peritonitis, which elicits a virulent acute inflammatory response and is an important
cause of hospitalization, catheter loss, and technique failure. The most common contaminated
micro-organisms are coagulase-negative Staphylococcus, S. aureus, Streptococcus, and Gram-
negative bacteria. Much less common are mycobacterium and fungal peritonitis. Skin organ‐
isms contamination including Staphylococcus, Corynebacterium, and Bacillus species cause mild
inflammatory responses. Exit site infection with Staphylococcus epidermidis or Pseudomonas
aeruginosa is difficult to treat, with frequent progression to tunnel infections and peritonitis.
Fungal peritonitis generally requires catheter removal. It is worth mentioned that sustained
inflammation is observed in patients on PD with peritonitis even after resolution of the clinical
symptoms of peritonitis [52]. The C-reactive protein (CRP) remains significantly higher than
baseline by day 42 after an episode of peritonitis [5]. Release of neutrophil gelatinase-associated
lipocalin (NGAL) into the peritoneal dialysate effluent (PDE) by HPMC is induced following
an acute episode of CAPD-related peritonitis, and is related to the up-regulation of the IL-1β
concentration [53]. Lipopolysaccharide (LPS), a major component of Gram-negative bacterial
cell walls, is a potent immuno-stimulatory product [54]. Endotoxemia is common in PD
patients and circulating LPS may derived from the gastrointestinal tract during enteric
peritonitis [55]. The level of circulating LPS correlates with the severity of systemic inflam‐
mation, suggesting that endotoxemia may contribute to accelerated atherosclerosis in PD
patients.
3.1.2. Endogenous modulators
Uremia is associated with the immune dysfunction and is a significant risk factor for cardio‐
vascular abnormalities and death in chronic kidney disease (CKD) patients [56], and this risk
is further increased when CKD has progressed to ESRD requiring dialysis. Dialysis decreases
the impact of uremia, yet does not remove it completely. In PD patients, uremia fuels the
inflammatory state and introduces stress on the peritoneum due to the formation of carbonyl
products. It accelerates the formation of advanced oxidation protein products (AOPP) and
AGE, that induces an upregulation of the receptors of advanced glycation end products
(RAGE) [57]. Binding of AGE to RAGE alone [58], or in combination with the Toll-like receptor
(TLR)s, elicits the inflammatory activity [59]. It has been suggested that the high-mobility
group box 1 protein (HMGB1) may play a central role in mediating inflammation, and
interactions involving the HMGB1-TLR-RAGE axis trigger NF-κB activation and proinflam‐
matory cytokines induction [60]. Cytotoxic injury to mesothelial cells induces ROS, depletes
ATP, and triggers the extracellular release of HMGB1, which initiates a chronic inflammatory
response [61]. Serum adipokine levels are significantly elevated in uremic patients with CKD
[62], and elevated plasma concentrations of adiponectin and leptin have been reported [63,
64]. Leptin activates immune system and serves as a mediator of inflammation [65]. Glucose-
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based PDF induces a higher leptin secretion by a murine adipocyte cell line 3T3-L1 compared
to dialysate with physiological glucose concentration via the hexosamine pathway [66]. We
have demonstrated that the full-length isoform of leptin receptor, Ob-Rb, is expressed in
HPMC and its expression is up-regulated following exposure to glucose [67]. Glucose increases
leptin synthesis by peritoneal adipocytes and the adipocyte-derived leptin can induce TGF-β
production by HPMC through the Ob-Rb [67]. Adiponectin exerts protective functions on
innate and adaptive immunity, including the reduction of phagocytic activity, IL-6 and TNF-
α production by macrophage, T-cell response, and the induction of anti-inflammatory
cytokines by monocytes, macrophages and dendritic cells [68]. In a recent study using rat PD
model, glucose-based PDF down-regulates adiponectin synthesis by adipocytes through an
increased ROS generation [69].
In uremic patients under PD, chronic inflammatory processes induce the oxidative stress,
generating excess ROS, reactive nitrogen species (RNS), and DNA-reactive aldehydes. These
pro-oxidants overwhelm in vivo antioxidant defenses, and lead to increased oxidative damage
of peritoneal structure and function [70]. The link between oxidative stress and inflammation
has been demonstrated in liver injury, where oxidative stress induces the proinflammatory
signaling and macrophage activation [71]. In HPMC, ROS amplifies the high glucose-induced
expression of fibronectin [72], angiotensin II (AngII) and TGF-β [44].
Heat-shock proteins (HSP), a marker of the cellular stress response, is the main effector of the
cellular reparative machinery. Induction of HSP expression will counteract cellular injury
caused by PDF exposure. PDF induces HSP release by cultured HPMC [73, 74]. In an experi‐
mental model of PD, PDF infusion causes cellular injury but also up-regulates HSP-72 [75]. In
HPMC under sublethal injury, secretion of HSP-72 correlates with the release of proinflam‐
matory IL-8 [76].
Breakdown products of the ECM during tissue injury, may serve as the endogenous modulator
of inflammation. There is growing evidence that ECM molecules may deliver proinflammatory
signals [77, 78]. In the context of PD, expression and release of hyaluronan (HA) and biglycan
(BGN) is well recognized. HPMC synthesize and secrete ECM proteins including BGN and
HA, which are detectable in PDE [19, 79, 80]. Under physiological conditions, HA is present
as an inert high-molecular-weight polymer. Upon tissue injury, HA is broken down into
inflammatory low-molecular-weight fragments, which activate the TLR4 and promote either
an inflammatory or a tissue-repair response [81, 82]. Other than HA, BGN also implicate in
modulating the proinflammatory functions. BGN can act as a “danger” motif, a potential innate
antigen analogous to pathogen-associated molecular pattern (PAMP), which signal through
TLR4 and TLR2 to initiate the inflammatory cascade [83]. BGN binds with TGF-β and TNF-α
to regulate the proinflammatory cytokine activity [84, 85]. Markedly elevated TNF-α and
IL-1β is found in PDE from CAPD patients with peritonitis [86]. The activity of proinflamma‐
tory master cytokine IL-1β is regulated by sequentially synthesis and cleavage of pro-IL-1 by
caspase-1 (also named as IL-1 converting enzyme) [87, 88]. The production of pro-IL-1 is
signaled by TLR and the activation of caspase-1 requires the assembly and activity of a cytosolic
multi-protein complex known as the inflammasome, consisting of nucleotide-binding oligo‐
merization-like receptor family members (NLRs) [89]. NLRP3 is the best characterized NLRs
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which recruits caspase-1 to the inflammasome. In macrophage, soluble BGN induces the
NLRP3 inflammasome, activating caspase-1 and releasing mature IL-1β [90]. Most notably,
the pro-inflammatory events initiated by HA or BGN are also ROS dependent [91]. Figure 2
illustrates the complex interaction amount various endogenous modulators in relation to
peritoneal inflammation.
Figure 2. Endogenous modulators in the regulation of peritoneal inflammation
4. Mediators
An array of inflammatory mediators is significantly induced or up-regulated following PD,
and is known to modulate the structure and function of the peritoneal membrane, as well as
the function of the downstream effectors of the inflammatory pathway. Of equally important,
these mediators also play a central role in the maintenance of homeostasis in peritoneum. These
mediators are either derived from plasma proteins or secreted by infiltrating or resident
peritoneal cells. While many of these inflammatory mediators have overlapped effects on the
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vasculature and on the recruitment of leukocytes, other mediators may perform additional
specific functions and are produced directly in response to particular stimulation by PD-
related modulators. It should be noted that some mediators can induce the production of other
inflammatory mediators and it is important to understand the logic underlying this hierarchy
of mediators induction. The soluble mediators of PD-related inflammation classified according
to their biochemical properties is shown in Table 1.
There are many other members in each category, only those commonly reported are listed.
Table 1. Mediators of PD-related inflammation
4.1. Acute phase proteins
Emerging evidences have suggested that acute phase proteins generated during PD may have
additional function instead of just serving as the markers of inflammation. CRP plays a
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proinflammatory role in activating monocyte chemotactic protein [92]. Data from studies on
endothelial cells, monocytes-macrophages and smooth muscle cells support a direct role for
CRP in atherogenesis [93-95]. NGAL has been evaluated as an urinary biomarker for detecting
the early onset of renal tubular cell injury [96]. In CAPD, NGAL in PDE is a marker for
neutrophil-dependent bacterial peritonitis, and is also synthesized by HPMC induced
specifically by IL1-β [53]. NGAL directly involves in the pathogenesis of CKD and cardiovas‐
cular abnormality [97].
Table 2. Effectors in PD-related Inflammation
4.2. Chemokines and circulating adhesion molecules
In response to modulators of peritoneal inflammation, chemokines are produced by peritoneal
cells including HPMC [98], macrophages [43], adipocytes [99], to control leukocyte extrava‐
sation and chemotaxis towards the affected tissues. These chemokines includes IL-8 [98, 100],
MCP-1 [98, 101], macrophage inhibitory factor (MIF) [102], and regulated upon activation
normal T cell expressed and secreted (RANTES) [98, 101]. Strikingly, HPMC express the α-
chemokine stromal derived factor-1 (SDF-1) [103]. The expression levels of SDF-1 is up-
regulated by TGF-β1 treatment, resulting in an increased migratory potential of HPMC, which
is suggested to be involved in the re-epithelialization of denuded basement membrane at the
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site of peritoneal injury [104]. Soluble adhesion molecules including soluble intercellular
adhesion molecule-1 (sICAM-1) [105] and soluble vascular cell adhesion molecule-1
(sVCAM-1) [106] are produced by endothelial cells during PD, and their concentration
correlates with atherogenesis or cardiovascular functions.
4.3. Complement components
Complement activation during PD plays key roles in the maintenance of host homeostasis by
eliminating infectious microorganisms and injured cells. Complement activation releases a
number of biologically active products that drive peritoneal inflammation [107]. The comple‐
ment fragments, C3a, C4a and C5a (also known as anaphylatoxins), are produced by several
pathways of complement activation. These complement components promote the recruitment
of granulocytes and monocytes, and induce mast-cell degranulation, thereby affecting the
vasculature of the peritoneum in PD. The synthesis of C3 and C4 by HPMC are regulated by
PDF [108]. In rodent model, blocking C5a reduces influx of neutrophils and improve ultrafil‐
tration [109]. Inhibiting the complement activation by complement regulators (CRegs), Crry
and CD59, may protect the peritoneal membrane from long-term PD injury [110].
4.4. Cytokines and adipokines
Numerous cytokines are produced by peritoneal cells, infiltrating macrophages or mast cells
(Table 1). These cytokines play pluripotent pleiotropic roles in the peritoneal inflammation,
participate in the host defense mechanisms and the induction of the acute-phase response.
During peritonitis, there is increased release of IL-1β, IL-6, TGF-β and TNF-α by HPMC [52].
These cytokines may autocrinally induce epithelial to mesenchymal transition (EMT) in
HPMC, and this further promotes peritoneal inflammation and fibrosis [29, 111, 112]. In the
uremic pre-dialysis and PD patients, there is increased peritoneal expression of the fibroblast
growth factor-2 (FGF-2) and VEGF [113]. Compared to patients dialysed with low-GDP
containing PDF, patients dialysed with less-biocompatible PDF have increased concentration
of TNF-α, hepatocyte growth factor (HGF), and IL-6 in the dialysate [102]. AGE and GDP in
PDF differentially regulate the synthesis of connective tissue growth factor (CTGF) by
peritoneal resident cells. The CTGF synthesis by HPMC can be further amplified by TGF-β
released from peritoneal fibroblast or endothelial cells [114]. Crosstalk among peritoneal cells
and their cytokines may amply the inflammatory cascade. The differential activation of
different transcriptional factors and the diverse response of HPMC towards CTGF, TGF-β and
VEGF, suggest that peritoneal cytokines have an overlapping and yet distinct role on peritoneal
target cells. Other than the cytokines, peritoneal adipocytes can mediate various physiological
processes through the secretion of an array of adipokines including leptin, adiponectin, apelin,
retinol-binding protein-4 (RBP-4) [103, 115]. These adipokines have distinct functions on
peritoneum during PD. For example, leptin augments myofibroblastic conversion of HPMC
[116]. The relative levels of leptin and adiponectin in dialysate from PD patients may indicate
the risk of cardiovascular disease [117].
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4.5. Lipid mediators
Two major classes of lipid mediators, eicosanoids and platelet-activating factors (PAF), are
derived from phosphatidylcholine, a member of the phospholipid family that is present in the
inner leaflet of cellular membranes. Prostaglandins E2 (PGE2) is generated from eicosanoids,
whereas PAF is produced by the acetylation of lysophosphatidic acid. PGE2 causes vasodila‐
tion and modulates the change of peritoneal permeability in PD after peritonitis [118]. PAF
activates several processes that occur during the inflammatory response, including the
recruitment of leukocytes, vascular permeability and platelet activation. Oxidative stress
during PD causes unrestrained synthesis of PAF through interfering the proper function of
alpha 1-proteinase inhibitor, a PAF inhibitor, [119]. Esterified eicosanoids are produced from
5-Lipoxygenase (5-LOX) by neutrophils after peritonitis, and enhance the generation of IL-8
and superoxide [120].
4.6. Proteolytic enzymes
Proteolytic enzymes have diverse roles in inflammation, in part through degrading ECM and
basement-membrane proteins. These proteases have important roles in many processes,
including host defense, tissue remodeling and leukocyte migration. Matrix metalloproteinase
(MMP) is the most important family of proteolytic enzymes in mesothelial homeostasis and
wound repair. Of equal important is the endogenous tissue inhibitors of metalloproteinase
(TIMP), which moderate MMP activity. The balance between MMPs and TIMPs, helps to
regulate ECM turnover during tissue remodeling in PD. MMP-2 has been associated with the
oxidative stress marker in PD [121]. Activation of MMP-2 causes peritoneal injury during
peritoneal dialysis in rats [122]. Neutral-pH PDF improves peritoneal function and decreases
MMP-2 in patients undergoing CAPD [123]. MMP-2 and TIMP-1 levels in peritoneal effluents
reflect solute transport rate and are associated with peritoneal injury [124]. Regression analysis
revealed that both the MMP-7 and TIMP-1, are excellent predictors of cellular stress in dialyzed
patients using HSP-27 as the marker [125]. The number of mast cells is increased in PD patients
[126], and mast cell tryptase is a serine protease implicated in promoting angiogenesis and
fibrosis [126, 127].
4.7. Vasoactive substances
Vasoactive amines modulate the vascular permeability, vasodilation, or vasoconstriction of
the peritoneal vasculature during PD, and are produced in an all-or-none manner during
degranulation from mast cells and platelets. PDF induces peritoneal histamine release from
mast cells [128], and this further causes calcium flux, which activates HPMC and influences
cytoskeleton organization [129]. The neuropeptide substance P exaggerates the affected
microvascular tone, albumin loss and reduced ultrafiltration in a rat PD model [128]. Plasma
levels of atrial natriuretic peptide (ANP), pro-renin activity (PRA), and ET are increased in
uremic patients on long-term CAPD, and suggesting the risk of development of myocardial
function [130]. AngII activates macrophages and fibroblast to secrete proinflammatory
cytokines, chemokines, and VEGF [131]. AngII plays important roles in regulating peritoneal
extracellular volume and in the development of peritoneal fibrosis [132, 133].
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5. Effectors
The effectors of PD inflammatory response are the residential peritoneal cells and the recruited
leukocytes. Residential peritoneal effector cells are adipocytes, endothelial cells, fibroblasts,
macrophages, mast cells and mesothelial cells. Recruited leukocytes include polymorphonu‐
clear cells (PMN), T or B lymphocytes, macrophages and mast cells. Table 2 shows the cell
types and their released mediators, which are of relevance to the PD-induced inflammation.
Upon PD, both the exogenous or endogenous modulators activate peritoneal adipocytes,
macrophages and mesothelial cells, which produce inflammatory cytokines, adipokines and
growth factors. These mediators will further promote the secretion of angiogenic factors,
fibrotic cytokines and growth factors, by fibroblasts, endothelial cells and mast cells through
paracrine interaction. In the meantime, residential HPMC, adipocyte and macrophage also
release chemotatic mediators to recruit the exogenous inflammatory immune effectors. All
these events orchestrate to amplify the inflammatory cascades and eventually lead to the loss
of ultrafiltration and development of peritoneal fibrosis.
6. New PDF and immune responses
Emerging evidences suggest the beneficial effects on peritoneal function by using new PDF
with decreasing acidity, reducing GDP concentration, and with non-glucose osmotic agents
such as amino acids or glucose polymers. In vitro cell culture studies have demonstrated
enhanced biocompatibility with improved survival of peritoneal cells exposed to new PDF
[134-136]. Data from animal models of PD using new PDF also have shown reduced fibrosis
and neoangiogenesis, improved macrophage function, and better maintained ultrafiltration
[137, 138]. In humans, the use of glucose-polymer-based solution reduced the cholesterol levels
with enhanced lipid oxidation and improved serum profiles of adipokines [139-141]. Despite
these beneficial effects, use of glucose-polymer-based solution may increase levels of AGE and
other immune mediators including IL-6, TNF-α and HA [142-144]. The use of amino-acid-
based PDE improves protein malnutrition but exerts negative metabolic effects of increasing
serum urea and homocysteine levels [145]. Moreover, PDE level of IL-6 is increased, reflecting
the activation of inflammatory response of the peritoneal membrane [146]. The use of glucose-
based neutral pH PDF achieves less activation of peritoneal membrane the best preservation
of its integrity. The levels of AGE, HA, VEGF and IL-6 are not altered and the effluent-derived
macrophage phagocytic function is enhanced [147-150].
7. Conclusion
The PD-related inflammation is an exceedingly complex process. Although some of the
destructive events of PD-induced inflammation can be prevented, nevertheless, other long-
term damage is understandably unavoidable. The incidences of peritonitis, exit site infection
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and catheter malfunction may be decreased with better patient education, optimal exit site
care, the use of oral prophylactic antibiotics after wet contamination, and the use of the
disconnect systems. The inflammatory modulators in the conventional PDF may be reduced
or removed by using novel PDF-based replacement of glucose with icodextrin and amino acids,
lactate with bicarbonate at a neutral to physiological pH.
There are potential therapeutic options to minimize peritoneal inflammation in PD patients,
but yet need extensive research for further confirmation [151]. Acute peritonitis may be
prevented by the use of chemokine receptor blockers, mast cell stabilizers or corticosteroid to
block excessive macrophage activity. Chronic PD-related inflammation may be targeted by
inhibiting various signaling pathways involved in the inflammatory cascade, or by the
introduction of anti-inflammatory agents including anti-RAGE antibodies, bone morphoge‐
netic protein-7 (BMP-7) or Smad7 transgene delivery.
Desperately, if patients have not been given kidney transplant, peritoneum fibrosis will be
developed eventually with long term PD. Even after kidney transplant, the restoration and
repair of the already injured and thickened peritoneum are still required. Thus, the uppermost
challenge is to preserve and at the best, to restore the peritoneum function. Stem cells trans‐
plantation either from bone marrow or using mesenchymal stem cells, although still in its
infancy, may be an attractive intervention for the repair or replenishment of the cellular
reservoir of multi-potential cells of the damaged peritoneal tissue. Further investigation along
this direction is warranted.
List of abbreviations
AGE Advanced glycation end products
Ang II Angiotensin II
ANP Atrial natriuretic peptide
AOPP Advanced oxidation protein products
BGN Biglycan
BMP-7 Bone Morphogenetic Protein-7
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CKD Chronic kidney disease
CRegs Complement regulators
CRP C-reactive protein
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ECM Extracellular matrix
EMT Epithelial to mesenchymal transition
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ER Endoplasmic reticulum
ESI Exit site infection
ESRD End-stage renal disease
ET Endothelin
FGF-2 Fibroblast growth factor-2
HA Hyaluronan
HD Hemodialysis
HGF Hepatocyte growth factor
HMGB1High-mobility group box 1 protein
HPMC Human peritoneal mesothelial cells
HSP Heat-shock proteins
iNOS Inducible nitric oxide synthase
IFN-γ Interferon- γ
IL Interleukin
ISPD International Society for Peritoneal Dialysis
5-LOX 5-Lipoxygenase
LPS Lipopolysaccharide
MCP-1 Monocyte chemotactic protein-1
MMP Metalloproteinase
NF-κB Nuclear factor-κB
NGAL Neutrophil gelatinase-associated lipocalin
NLRs Nucleotide-binding oligomerization-like receptor family members
PAF Platelet-activating factors
PAMP Pathogen-associated molecular patterns
PD Peritoneal dialysis
PDE Peritoneal dialysate effluent
PGE2 Prostaglandins E2
PDF Peritoneal dialysis fluid
PMN Polymorphonuclear cells
PRA Pro-renin activity
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RAGE Receptors of advanced glycation end products
RANTES Regulated upon activation normal T cell expressed and secreted
RBP-4 Retinol-binding protein-4
RNS Reactive nitrogen species
ROS Reactive oxygen species
RRF Renal replacement therapy
SDF-1 Stromal derived factor-1
sICAM-1 Soluble intercellular adhesion molecule-1
sVCAM-1 Soluble vascular cell adhesion molecule-1
TGF-β Transforming growth factor-β
TIMP Tissue inhibitors of metalloproteinases
TLR Toll-like receptor
TNF-α Tumor necrosis factor-α
VEGF Vascular endothelial growth factor
ZO-1 Zonula occludens protein-1
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